IASLC Fall Newsletter

The IASLC 19th World Conference on Lung Cancer (WCLC 2018) in Toronto was an unbelievable success, both scientifically and financially speaking, with nearly 7,500 participants, outstanding plenary sessions and a scientific program that easily ranks among the best that has ever delivered at one of our annual meetings.

Lung cancer patients with severe disabilities underwent less staging work-up and treatment and had slightly higher overall mortality compared to people with no disability.

In association with 2018’s Lung Cancer Awareness Month (LCAM), an annual event that occurs each November, the Lung Cancer Awareness Month Coalition (LCAMC) has unveiled new Patient-Provider Cards, a resource to assist both lung cancer patients and providers in navigating the complex dynamics of lung cancer detection, diagnosis, advocacy and treatment.

Elderly patients with limited-stage small cell lung cancer (LS-SCLC) showed similar survival and toxicity compared to their younger counterparts when treated with concurrent chemo-radiotherapy.

Survivors, Advocates Kick Off Awareness Month at National Press Club Event

The International Association for the Study of Lung Cancer (IASLC) today issued a statement on lung cancer screening with low-dose computed tomography (LDCT)* based on results from the Dutch-Belgian NELSON lung cancer screening trial presented at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada.